Skip to main content
SpringerLink
Log in

Differenzialtherapie der Herzinsuffizienz

Welche Substanz für welchen Patienten?

Differential therapy of heart failure—Which drug for which patient?

  • Schwerpunkt: Was ist gesichert in der Therapie?
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Leitlinien zur medikamentösen Behandlung der Herzinsuffizienz werden immer noch unvollständig umgesetzt. Folgende Gründe können eine Rolle spielen:

  1. 1.

    Bestimmte Patienten wie ältere Menschen und Frauen waren in großen Interventionsstudien unterrepräsentiert, weshalb die Validität der Daten für diese Patienten kritisch hinterfragt werden muss.

  2. 2.

    Therapieentscheidungen werden zudem durch Begleiterkrankungen wie Niereninsuffizienz, obstruktive Atemwegserkrankungen (COPD, Asthma bronchiale), Apoplex und Diabetes mellitus beeinflusst.

Wir diskutieren die Bedeutung für die Differenzialtherapie der Herzinsuffizienz.

Abstract

The implementation of guidelines for medical therapy of heart failure may be problematic for the following reasons:

1.:

Elderly patients and women were underrepresented in large clinical trials which may limit their therapeutic impact in these patients.

2.:

Therapeutic decisions are influenced by co-morbidities like renal failure, obstructive airway disease (COLD, Asthma), stroke, and diabetes mellitus.

We therefore discuss the differential therapy of heart failure in view of particular patient subgroups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3a, b
Abb. 4
Abb. 5

Literatur

  1. Hoppe UC, Erdmann E (2001) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Deutsche Gesellschaft für Kardiologie. Z Kardiol 90: 218–237

    Article  CAS  PubMed  Google Scholar 

  2. Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 22: 1527–1560

    Article  CAS  PubMed  Google Scholar 

  3. American College of Cardiology/American Heart Association task force on practice guidelines (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Executive summary. Circulation 104: 2996–3007

    CAS  PubMed  Google Scholar 

  4. Komajda M, the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology (2003) The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24: 464–474

    Article  CAS  PubMed  Google Scholar 

  5. Taubert G, Bergmeier C, Andresen H (2001) Clinical profile and management of heart failure: rural community hospital vs metropolitan heart center. Eur J Heart Fail 3: 611–617

    Article  CAS  PubMed  Google Scholar 

  6. Werner N, Böhm M (2004) ACE-Hemmertherapie bis ans Lebensende? Dtsch Med Wochenschr 129: 1513–1518

    Article  CAS  PubMed  Google Scholar 

  7. Shekelle PG, Rich MW, Morton SC et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41: 1529–1538

    Article  CAS  PubMed  Google Scholar 

  8. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347: 1403–1411

    Article  CAS  PubMed  Google Scholar 

  9. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878

    Article  CAS  PubMed  Google Scholar 

  10. Wuttke H, Rau T, Heide R et al. (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72: 429–437

    Article  CAS  PubMed  Google Scholar 

  11. Carluccio M, Soccio M, De Caterin R (2001) Aspects of gene polymorphism in cardiovascular disease: the renin-angiotensin-system. Eur J Clin Invest 31: 476–488

    Article  CAS  PubMed  Google Scholar 

  12. Bristow M (2003) Antiadrenergic therapy of chronic heart failure. Surprises and new opportunities. Circulation 107: 1100–1102

    Article  PubMed  Google Scholar 

  13. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004–1009

    Article  PubMed  Google Scholar 

  14. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation 104: 1985–1991

    CAS  PubMed  Google Scholar 

  15. Standl E, Eckert S, Fuchs C et al. (2003) Diabetes mellitus und Herz. In: Scherbaum WA, Landgraf R (Hrsg) Evidenzbasierte Diabetes-Leitlinie DDG. Deutsche Diabetes-Gesellschaft

  16. Nesto RW, Bell D, Bonow RO et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941–2948

    Article  PubMed  Google Scholar 

  17. Glaab T, Weiss T (2004) Einsatz von β-Blockern bei kardiovaskulären Erkrankungen und Asthma bronchiale/COPD. Internist. 45: 221–227

    Google Scholar 

  18. Salpeter S, Ormiston T, Salpeter E (2004) Cardiovascular Effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest 125: 2309–2321

    Article  CAS  PubMed  Google Scholar 

  19. Chen J, Radford M, Wang Y, Marciniak T, Krumholf H (2001) Effectiveness of β-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37: 1950–1956

    Article  CAS  PubMed  Google Scholar 

  20. Fournier A, Messerli FH, Achard JM, Fernandez L (2004) Cerebroprotection mediated by angiotensin II. A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43: 1343–1347

    Article  PubMed  Google Scholar 

  21. Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (2003) Primäre und sekundäre Prävention der zerebralen Ischämie. In: Diener HC (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart, S 129–144

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Herzzentrum, Georg-August-Universität Göttingen

    W. Schillinger, H. P. Hermann &  G. Hasenfuß

  2. Herzzentrum, Kardiologie und Pneumologie, Georg-August-Universität, Robert-Koch-Straße 40, 37099, Göttingen

    G. Hasenfuß

Authors
  1. W. Schillinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. P. Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Hasenfuß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Hasenfuß.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schillinger, W., Hermann, H.P. & Hasenfuß, G. Differenzialtherapie der Herzinsuffizienz. Internist 45, 1378–1387 (2004). https://doi.org/10.1007/s00108-004-1290-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-004-1290-8

Schlüsselwörter

Keywords

Search

Navigation